<DOC>
	<DOCNO>NCT02980692</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multiple-dose , phase 2b study demonstrate safety efficacy SUNPG1623</brief_summary>
	<brief_title>Efficacy Safety Study SUNPG1623</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Subject provide write informed consent Subject ≥ 18 year age time Screening Subject must stable dose NSAID ≥ 4 week prior initiation IMP Subject negative evaluation TB within 4 week initiate IMP Subject plan surgical intervention Baseline Week 24 evaluation pretreatment condition Subject active infection history infection Subject concurrent medical condition uncontrolled , clinically significant systemic disease Subject know history infection hepatitis B , hepatitis C , human immunodeficiency virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>